Signals
3IgG4-related disease enters real prescribing territory
Inebilizumab IgG4-RD pivotal data, rituximab maintenance protocols, and structured diagnostic pathways are reshaping IgG4-related disease management.
Hidradenitis suppurativa biologic options widen past TNF
IL-17-class secukinumab and bimekizumab approvals plus emerging novel mechanism programs are restructuring hidradenitis suppurativa management.
Sjogren disease therapy enters real prescribing territory
First positive pivotal readouts in Sjogren disease are establishing a category that has had no specific systemic therapy for decades.
Snapshots
1Explained
4What is systemic sclerosis?
Plain-language primer on systemic sclerosis (scleroderma), why it affects multiple organ systems, and what modern therapy can offer.
What is ANCA-associated vasculitis?
Plain-language primer on ANCA-associated vasculitis, why it can affect multiple organs, and how modern therapy works.
What is lupus nephritis?
Plain-language primer on lupus nephritis, why kidney involvement is a turning point in lupus, and how modern therapy works.
What is Sjogren disease?
Plain-language primer on Sjogren disease, why it has been hard to treat, and what is changing.